Eli Lilly Bets up to $7B on Cancer-Fighting Gene Therapy

Eli Lilly is making a multi-billion dollar push beyond its blockbuster weight-loss drugs, targeting the next generation of cancer therapies with its second major oncology acquisition of the year.

Eli Lilly and Co. agreed to acquire Kelonia Therapeutics for up to $7 billion, securing a promising in vivo CAR-T platform that could challenge existing cell therapies and significantly expand Lilly’s oncology pipeline beyond its dominant GLP-1 franchise. The deal, announced this week, is one of the largest in the in vivo cell therapy space and signals Lilly’s intent to become a major player in oncology.

“This is an early-stage deal that we view as constructive and positive to continue to expand and diversify the pipeline for long-term growth beyond the GLP-1 franchise,” UBS analysts wrote in a research note.

The acquisition is structured with a $3.25 billion upfront payment and up to $3.75 billion in additional payments tied to clinical, regulatory, and commercial milestones. Kelonia’s lead program is a Phase I in vivo CAR-T therapy targeting BCMA for multiple myeloma. Early data presented in December 2025 showed all four patients treated achieved minimal residual disease-negative responses, a key marker of treatment effectiveness.

For investors, the move highlights Lilly’s strategy to mitigate long-term risk by diversifying away from its reliance on GLP-1 weight-loss drugs like Zepbound. While the GLP-1 market is thriving, with analysts forecasting Lilly’s franchise sales to reach $45 billion by 2031, the company is proactively building its next growth pillar in a global oncology market projected by Fortune Business Insights to hit nearly $700 billion by 2034.

A New Frontier in Cell Therapy

Kelonia’s technology represents a significant potential advance in CAR-T (Chimeric Antigen Receptor T-cell) therapy, a treatment that reprograms a patient's own immune cells to fight cancer. Unlike conventional CAR-T therapies that require extracting a patient's cells and engineering them in a lab—a costly and time-consuming process—Kelonia’s in vivo approach delivers the therapy directly into the body as an off-the-shelf injection.

The platform uses a proprietary lentiviral delivery system, called iGPS, to precisely target immune cells. This method contrasts with the lipid nanoparticle technologies used by some competitors. Critically, Kelonia’s treatment does not require lymphodepleting chemotherapy, a harsh pre-conditioning regimen for patients. Early safety data has been encouraging, with no instances of high-grade cytokine release syndrome or neurotoxicity, two severe side effects that have plagued other cell therapies.

“Acknowledging the field is still very early w/ small patient numbers, we believe the Kelonia program acquired has some of the strongest proof-of-concept to date,” UBS analysts added.

Building an Oncology Powerhouse

This acquisition is the latest in a series of moves by Lilly to bolster its cancer-fighting capabilities. In February, the company purchased Orna Therapeutics for $2.4 billion, another firm in the cell therapy space using a different technological approach. This strategy of acquiring multiple complementary technologies gives Lilly several shots on goal in the highly competitive field.

The broader market has taken notice of this trend. When Pfizer completed its $43 billion acquisition of Seagen in 2023, it lifted valuations across the biotech sector. Lilly’s multi-billion-dollar bet on Kelonia is expected to similarly spotlight the in vivo therapy space, potentially creating opportunities for investors in other publicly traded companies with related technologies.

Lilly’s stock, which has fallen about 17% since its record high in November, now trades at 25 times forward earnings. While this is a premium to the S&P 500’s multiple of 21, it is below the stock's recent historical average. The market appears to have concerns about rising competition in the GLP-1 space, but the Kelonia deal demonstrates a clear path for long-term growth outside of weight-loss drugs, making the current valuation potentially attractive for investors who missed the stock's previous five-year rally.

This article is for informational purposes only and does not constitute investment advice.